We are live on ! Find out more
BEAM icon

Beam Therapeutics

224 hedge funds and large institutions have $2.6B invested in Beam Therapeutics in 2022 Q3 according to their latest regulatory filings, with 44 funds opening new positions, 74 increasing their positions, 65 reducing their positions, and 25 closing their positions.

New
Increased
Maintained
Reduced
Closed

247% more call options, than puts

Call options by funds: $53.9M | Put options by funds: $15.5M

76% more first-time investments, than exits

New positions opened: 44 | Existing positions closed: 25

24% more capital invested

Capital invested by funds: $2.09B → $2.6B (+$509M)

14% more repeat investments, than reductions

Existing positions increased: 74 | Existing positions reduced: 65

9% more funds holding

Funds holding: 205224 (+19)

0% more funds holding in top 10

Funds holding in top 10: 33 (0)

0.26% less ownership

Funds ownership: 77.81%77.55% (-0.26%)

Holders
224
Holders Change
+19
Holders Change %
+9.27%
% of All Funds
3.86%
Holding in Top 10
3
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.05%
New
44
Increased
74
Reduced
65
Closed
25
Calls
$53.9M
Puts
$15.5M
Net Calls
+$38.4M
Net Calls Change
+$44.4M
Name Holding Trade Value Shares
Change
Change in
Stake
Tudor Investment Corp
76
Tudor Investment Corp
Connecticut
$1.95M +$2.33M +40,839 New
State of New Jersey Common Pension Fund D
77
State of New Jersey Common Pension Fund D
New Jersey
$1.87M -$1.44M -25,209 -39%
Carson Wealth (CWM LLC)
78
Carson Wealth (CWM LLC)
Nebraska
$1.7M -$66.5K -1,165 -3%
TRCT
79
Tower Research Capital (TRC)
New York
$1.64M +$586K +10,281 +43%
MIM
80
MetLife Investment Management
New Jersey
$1.64M +$75.6K +1,325 +4%
AIG
81
American International Group
New York
$1.44M +$24.3K +426 +1%
EHI
82
Eagle Health Investments
Connecticut
$1.38M
Invesco
83
Invesco
Georgia
$1.37M +$196K +3,441 +14%
CGL
84
Clarius Group LLC
Washington
$1.34M
CRB
85
Chad R. Baker
$1.31M
Capital Fund Management (CFM)
86
Capital Fund Management (CFM)
France
$1.31M -$160K -2,813 -9%
T. Rowe Price Associates
87
T. Rowe Price Associates
Maryland
$1.29M +$203K +3,560 +15%
Manulife (Manufacturers Life Insurance)
88
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$1.2M -$26.7K -468 -2%
DekaBank Deutsche Girozentrale
89
DekaBank Deutsche Girozentrale
Germany
$1.2M +$628K +11,000 +79%
Royal Bank of Canada
90
Royal Bank of Canada
Ontario, Canada
$1.17M -$394K -6,901 -22%
IBT
91
International Biotechnology Trust
United Kingdom
$1.12M +$1.29M +22,590 +2,482%
Neuberger Berman Group
92
Neuberger Berman Group
New York
$1.06M -$4.11K -72 -0.3%
TI
93
Trexquant Investment
Connecticut
$1.06M -$2.02M -35,443 -61%
EAM
94
Erste Asset Management
Austria
$1.03M +$388K +6,800 +46%
MOACM
95
Mutual of America Capital Management
New York
$1.02M +$1.23M +21,505 New
Victory Capital Management
96
Victory Capital Management
Texas
$1.01M -$21.9K -384 -2%
State Board of Administration of Florida Retirement System
97
State Board of Administration of Florida Retirement System
Florida
$1M -$254K -4,450 -17%
Wells Fargo
98
Wells Fargo
California
$1M -$3.08M -54,017 -72%
Janus Henderson Group
99
Janus Henderson Group
United Kingdom
$978K +$478K +8,383 +69%
Massachusetts Financial Services
100
Massachusetts Financial Services
Massachusetts
$922K +$1.1M +19,350 New

BEAM Hedge Fund Activity: Q3 2022 in Review

224 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Beam Therapeutics (BEAM) for Q3 2022, worth a combined $2.6B — up 24% from $2.09B a quarter earlier.

Buyers outnumbered sellers: 44 funds opened new BEAM positions and 25 closed out — a net gain of 19 holders — while 74 added to existing stakes and 65 trimmed.

The largest buyer was Vanguard Group, adding an estimated $52.9M. The largest seller was Temasek Holdings, cutting an estimated $62.3M.

  • 224 institutional investors held Beam Therapeutics (BEAM) as of Q3 2022, up from 205 in Q2 2022.
  • Funds reported $2.6B of Beam Therapeutics stock for Q3 2022, up 24% quarter-over-quarter.
  • 44 funds opened new Beam Therapeutics positions in Q3 2022 and 25 closed out, a net change of +19 holders.
  • The largest Beam Therapeutics buyer in Q3 2022 was Vanguard Group, an estimated $52.9M added.
  • The largest Beam Therapeutics seller in Q3 2022 was Temasek Holdings, an estimated $62.3M sold.

Based on aggregated 13F filings for Q3 2022.